Literature DB >> 2932416

Bactericidal activity of ciprofloxacin in serum and urine against Escherichia coli, Pseudomonas aeruginosa, Klebsiella pneumoniae, Staphylococcus aureus and Streptococcus faecalis.

H Lagast, M Husson, J Klastersky.   

Abstract

Ten volunteers received three doses of 500 mg ciprofloxacin, orally every 12 hours. After the last dose, mean serum levels were (mg/l +/- SD) 2.4 +/- 0.83 at 1 h; 0.91 +/- 0.30 at 4 h and 0.18 +/- 0.04 at 12 h. At 1 h the median serum bactericidal activity was satisfactory only against the Escherichia coli (1:256) and Klebsiella pneumoniae (1:128). In urine collected from 0 to 4 h and 8 to 12 h after the last dose, the mean ciprofloxacin level was respectively 482.5 +/- 324.7 and 80.9 +/- 48.2 mg/l +/- SD. Bactericidal activity in urine was high even against the least susceptible species tested: Pseudomonas aeruginosa, Staphylococcus aureus and Streptococcus faecalis. A post antibiotic effect was demonstrated in 22 out of the 29 strains tested, ranging mainly from 1 to 3 h. Ciprofloxacin 500 mg orally twice a day is a bactericidal regimen against a wide range of urinary pathogens but has a limited systemic activity.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2932416     DOI: 10.1093/jac/16.3.341

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  8 in total

1.  Serum bactericidal activity of ciprofloxacin and ofloxacin in volunteers.

Authors:  K Machka; D Milatovic
Journal:  Eur J Clin Microbiol       Date:  1987-02       Impact factor: 3.267

2.  Impact of the dosage schedule on the efficacy of ceftazidime, gentamicin and ciprofloxacin in Klebsiella pneumoniae pneumonia and septicemia in leukopenic rats.

Authors:  R Roosendaal; I A Bakker-Woudenberg; M van den Berghe-van Raffe; J C Vink-van den Berg; B M Michel
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-10       Impact factor: 3.267

3.  Comparative serum bactericidal activities of three doses of ciprofloxacin administered intravenously.

Authors:  M Dan; F Poch; C Quassem; R Kitzes
Journal:  Antimicrob Agents Chemother       Date:  1994-04       Impact factor: 5.191

4.  Bactericidal activity and killing rate of serum in volunteers receiving ciprofloxacin alone or in combination with vancomycin.

Authors:  P Van der Auwera; J Klastersky
Journal:  Antimicrob Agents Chemother       Date:  1986-12       Impact factor: 5.191

5.  Pharmacokinetics and serum bactericidal titers of ciprofloxacin and ofloxacin following multiple oral doses in healthy volunteers.

Authors:  D Israel; J G Gillum; M Turik; K Harvey; J Ford; H Dalton; M Towle; R Echols; A H Heller; R Polk
Journal:  Antimicrob Agents Chemother       Date:  1993-10       Impact factor: 5.191

6.  Bactericidal activity of ciprofloxacin, norfloxacin and ofloxacin in serum and urine after oral administration to healthy volunteers.

Authors:  H J Zeiler; D Beermann; W Wingender; D Förster; P Schacht
Journal:  Infection       Date:  1988       Impact factor: 3.553

7.  Comparative efficacy of ciprofloxacin, ceftazidime and gentamicin, given alone or in combination, in a model of experimental septicemia due to Klebsiella pneumoniae in neutropenic mice.

Authors:  M Trautmann; O Brückner; R Marre; H Hahn
Journal:  Infection       Date:  1988       Impact factor: 3.553

Review 8.  Ciprofloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  D M Campoli-Richards; J P Monk; A Price; P Benfield; P A Todd; A Ward
Journal:  Drugs       Date:  1988-04       Impact factor: 9.546

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.